SolasCure Completes Phase II Clinical Trial, Demonstrating Accelerated Healing With Aurase Wound Gel

Biotechnology company's investigational product shows significant improvements in wound debridement and healing rates compared to standard of care.

Feb. 24, 2026 at 2:04pm

Got story updates? Submit your updates here. ›

SOLASCURE Ltd, a biotechnology company developing a novel treatment to transform chronic wound healing, has announced the successful completion of its second Phase II clinical trial, CLEANVLU2. The study demonstrated that its investigational product, Aurase Wound Gel (AWG), heals chronic wounds at a faster rate than current standard of care, providing clinical validation of its ability to deliver continuous enzymatic debridement while simultaneously activating wound healing.

Why it matters

Chronic wounds remain a significant and growing unmet medical need, affecting millions of patients worldwide and placing a substantial burden on healthcare systems. Current therapies primarily focus on wound bed preparation rather than directly stimulating the biological processes required for healing. The positive results from SolasCure's clinical trial highlight the potential of AWG to address multiple aspects of wound care within a single therapeutic, which could lead to improved patient outcomes and reduced healthcare costs.

The details

At higher concentrations of tarumase, AWG demonstrated significantly enhanced clinical activity, debriding sloughy wounds 22 times faster and achieving rates of healing seven times faster than standard of care (hydrogel in combination with advanced moist wound healing dressings and compression bandaging systems). After 26 days, AWG achieved 65% debridement versus 9% in control (p=0.005) and 58% wound area reduction versus 15% in control (p=0.022). The results indicate a dual mechanism of action where, in addition to continuously removing necrotic tissue, API tarumase activates PAR2 receptors involved in tissue repair, initiating healing pathways from the first application. AWG maintained an excellent safety profile, caused no additional pain to patients, and was associated with improvements in quality of life across physical, psychological, and daily living measures.

  • The CLEANVLU2 study was completed in February 2026.

The players

SOLASCURE Ltd

A biotechnology company developing a novel treatment to transform chronic wound healing.

Aurase Wound Gel (AWG)

SolasCure's investigational product that combines a proprietary hydrogel formulation with the active pharmaceutical ingredient tarumase.

Rob Kirsner, M.D., PhD

Head of Medical Advisory Board at SolasCure, Chairman and Harvey Blank Professor of Dermatology at the University of Miami.

Got photos? Submit your photos here. ›

What they’re saying

“These Phase II results represent a highly encouraging advance in the treatment of chronic wounds. From a clinical perspective, the data demonstrate very effective debridement alongside meaningful activation of the biological processes leading to healing.”

— Rob Kirsner, M.D., PhD, Head of Medical Advisory Board at SolasCure, Chairman and Harvey Blank Professor of Dermatology at the University of Miami

What’s next

The full clinical data from CLEANVLU2 will be submitted for peer-reviewed publication.

The takeaway

SolasCure's Aurase Wound Gel has the potential to address multiple aspects of chronic wound care, including wound bed preparation, debridement, and sustained healing, within a single therapeutic. If further clinical trials continue to demonstrate the product's efficacy and safety, it could provide a significant advancement in the treatment of chronic wounds, which remain a major unmet medical need.